Locations
South San Francisco, CA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Other
founded in
2020
Trishula Therapeutics is a clinical-stage biopharmaceutical company focused on developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving cancer treatment outcomes. The company targets immune evasion mechanisms in the tumor microenvironment, with TTX-030 currently undergoing multiple clinical trials, including a randomized Phase 2 study in frontline metastatic pancreatic cancer. Their innovative approach differentiates them in the oncology space, and they are gaining traction with promising early-phase data and ongoing studies. Trishula's market position is strengthened by its commitment to advancing immunotherapy solutions for patients with advanced cancers.
Something looks off?